SAN DIEGO, Apr 27, 2010 (BUSINESS WIRE) --Illumina, Inc. (NASDAQ:ILMN) today announced shipment of HiScanSQ, the first instrument to integrate microarray analysis and next-generation sequencing in a modular design that can evolve with changing research needs. HiScanSQ is designed for smaller core labs that don't want to purchase separate platforms to run sequencing and microarray experiments; groups that primarily run arrays but are looking to move into sequencing for the first time; and facilities that run both arrays and capillary electrophoresis sequencing and are looking to add high-throughput sequencing.
The HiScanSQ system has two components: the HiScan Reader, a high-performance array scanner that can also image sequencing flow cells and the SQ Module, an add-on fluidics device that enables genomic-scale sequencing. The publication-proven HiScan Reader functions independently as a high-speed, precision micro-array scanner for Illumina's BeadArray products. With the SQ module, the system switches to perform Illumina's sequencing-by-synthesis (SBS), the most widely adopted next-generation sequencing technology, generating 50 Gb of data per paired-end flow cell. Together, these complementary technologies provide a powerful approach to genetic discovery and validation.
"The idea behind the HiScanSQ platform is to give people flexibility," said Tristan Orpin, senior vice president, Commercial Operations at Illumina. "The falling cost of sequencing has made arrays and sequencing complementary, so many core labs are looking for a system that will allow them to perform some initial discovery with arrays, and then use sequencing to further characterize or validate the results in-house. For instance, researchers can leverage targeted resequencing to follow-on their genome wide association study or transition between array-based and sequencing-based gene expression."
Researchers can minimize hands-on time through a number of user interface features that automate and streamline HiScanSQ workflow including a touch screen interface, pre-configured plug and play reagents, and data analysis software to allow users to visually integrate sequencing and array data.
For more information on Illumina HiScanSQ, please visit http://www.illumina.com/HiScanSQ.
About Illumina
Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.
Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in new product development and manufacturing and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update any forward-looking statements after the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors:
Peter J. Fromen, 858-202-4507
Sr. Director, Investor Relations
pfromen@illumina.com
Media:
Wilson Grabill, 858-882-6822
Senior Manager, Public Relations
wgrabill@illumina.com
